{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:49:25Z","timestamp":1788364165269,"version":"build-2803163510"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T00:00:00Z","timestamp":1661299200000},"content-version":"vor","delay-in-days":235,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The randomized phase 3 CeTeG\/NOA-09 trial assessed whether CCNU plus temozolomide was superior to temozolomide alone in newly diagnosed MGMT promoter methylated glioblastoma patients. Survival was significantly improved from 31.4 months (temozolomide) to 48.1 months (CCNU plus temozolomide). In view of this encouraging data, we assessed safety and efficacy of this regimen under real-life conditions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively collected clinical and radiographic data from adult newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma patients from five neuro-oncology centers in Germany. For inclusion in our analysis, treatment with CCNU and temozolomide had to be performed for at least six weeks (one course).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Seventy patients were included. Median progression-free survival was 14.4 months and median overall survival 33.8 months. Patients with TTFields treatment for at least 8 weeks and CCNU plus temozolomide (n\u2005=\u200522, 31%) had a prolonged progression-free survival compared to those with TTFields treatment for less than eight weeks (n\u2005=\u200548, 69%) (21.5 versus 11.2 months; P\u2005=\u2005.0105). In a multivariable Cox regression analysis, TTFields treatment for eight weeks or longer together with CCNU plus temozolomide and a Karnofsky performance score\u2005\u2265\u200590% were independent prognostic factors for progression-free and overall survival. Pseudoprogression occurred in n\u2005=\u200516 (33%) of investigated n\u2005=\u200549 (70%) patients. In n\u2005=\u200531 (44%) patients high-grade hematotoxicity was observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The results from this multicentric trial indicate that\u2014under real-life conditions\u2014toxicity and survival estimates are comparable to the CeTeG\/NOA-09 trial. TTFields therapy for at least eight weeks in combination with this regimen was independently associated with prolonged survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdac137","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T02:28:12Z","timestamp":1661308092000},"source":"Crossref","is-referenced-by-count":10,"title":["First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed <i>MGMT<\/i> promoter methylated <i>IDH<\/i> wildtype glioblastoma"],"prefix":"10.1093","volume":"4","author":[{"given":"Lazaros","family":"Lazaridis","sequence":"first","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Bumes","sequence":"additional","affiliation":[{"name":"Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg , Regensburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothee","family":"C\u00e4cilia Spille","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital M\u00fcnster , M\u00fcnster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital of W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sina","family":"Heider","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Hospital Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarina","family":"Agkatsev","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Blau","sequence":"additional","affiliation":[{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK)"},{"name":"Institute of Neuropathology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Oster","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Feldheim","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3460-0640","authenticated-orcid":false,"given":"Walter","family":"Stummer","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital M\u00fcnster , M\u00fcnster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almuth Friederike","family":"Kessler","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital of W\u00fcrzburg , W\u00fcrzburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Seidel","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiation Oncology, University Hospital Leipzig , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Grauer","sequence":"additional","affiliation":[{"name":"Department of Neurology with Institute of Translational Neurology, University Hospital M\u00fcnster , M\u00fcnster , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3894-5053","authenticated-orcid":false,"given":"Peter","family":"Hau","sequence":"additional","affiliation":[{"name":"Department of Neurology and Wilhelm Sander-NeuroOncology Unit, University Hospital Regensburg , Regensburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Sure","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"},{"name":"Department of Neurosurgery and Spine Surgery, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"Center for Translational Neuro- and Behavioral Sciences (C-TNBS) , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Keyvani","sequence":"additional","affiliation":[{"name":"Institute of Neuropathology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Herrlinger","sequence":"additional","affiliation":[{"name":"Division of Clinical Neurooncology, Department of Neurology and Center for Integrated Oncology, University Hospital Bonn , Bonn , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stuschke","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, University Medicine Essen, University Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"},{"name":"Department of Nuclear Medicine, University Medicine Essen, University Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius","family":"Deuschl","sequence":"additional","affiliation":[{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"},{"name":"Institute for Diagnostic and Interventional Radiology and Neuroradiology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella","family":"Breuer","sequence":"additional","affiliation":[{"name":"Institute of Neuroradiology, University Hospital Frankfurt , Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Hattingen","sequence":"additional","affiliation":[{"name":"Institute of Neuroradiology, University Hospital Frankfurt , Frankfurt , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Scheffler","sequence":"additional","affiliation":[{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK)"},{"name":"German Cancer Research Center (DKFZ) , Heidelberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sied","family":"Kebir","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Glas","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Division of Clinical Neurooncology, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK), Partner Site University Medicine Essen , Essen , Germany"},{"name":"DKFZ-Division Translational Neurooncology at the West German Cancer Center (WTZ), DKTK Partner Site, University Medicine Essen, University Duisburg-Essen , Essen , Germany"},{"name":"German Cancer Consortium (DKTK)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,24]]},"reference":[{"issue":"8","key":"2022121516332435000_CIT0001","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"issue":"10172","key":"2022121516332435000_CIT0002","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet."},{"issue":"27","key":"2022121516332435000_CIT0003","doi-asserted-by":"crossref","first-page":"4412","DOI":"10.1200\/JCO.2006.06.9104","article-title":"Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03","volume":"24","author":"Herrlinger","year":"2006","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022121516332435000_CIT0004","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2022121516332435000_CIT0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00432-019-03106-8","article-title":"Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma","volume":"146","author":"Lazaridis","year":"2020","journal-title":"J Cancer Res Clin Oncol."},{"issue":"8","key":"2022121516332435000_CIT0006","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol."},{"issue":"2","key":"2022121516332435000_CIT0007","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13311-016-0507-6","article-title":"Modified criteria for radiographic response assessment in glioblastoma clinical trials","volume":"14","author":"Ellingson","year":"2017","journal-title":"Neurotherapeutics."},{"issue":"3","key":"2022121516332435000_CIT0008","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00259-018-4207-9","article-title":"Joint EANM\/EANO\/RANO practice guidelines\/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [(18)F]FDG: version 1.0","volume":"46","author":"Law","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"9","key":"2022121516332435000_CIT0009","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-15-1334","article-title":"Late pseudoprogression in glioblastoma: diagnostic value of dynamic O-(2-[18F]fluoroethyl)-l-tyrosine PET","volume":"22","author":"Kebir","year":"2016","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2022121516332435000_CIT0010","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.2967\/jnumed.111.098590","article-title":"Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-l-tyrosine PET in comparison to MRI","volume":"53","author":"Galldiks","year":"2012","journal-title":"J Nucl Med."},{"issue":"10","key":"2022121516332435000_CIT0011","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med."},{"issue":"10","key":"2022121516332435000_CIT0012","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med."},{"issue":"10","key":"2022121516332435000_CIT0013","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"2022121516332435000_CIT0014","doi-asserted-by":"crossref","first-page":"vi55","DOI":"10.1093\/neuonc\/noab196.217","article-title":"A randomized phase 3 study of nivolumab or placebo combined with radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma with methylated MGMT promoter: CheckMate 548 [abstract]","volume":"23","author":"Weller","year":"2021","journal-title":"Neuro Oncol."},{"issue":"3","key":"2022121516332435000_CIT0015","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s00062-017-0584-x","article-title":"Incidence of tumour progression and pseudoprogression in high-grade gliomas: a systematic review and meta-analysis","volume":"28","author":"Abbasi","year":"2018","journal-title":"Clin Neuroradiol."},{"key":"2022121516332435000_CIT0016","doi-asserted-by":"crossref","first-page":"103188","DOI":"10.1016\/j.critrevonc.2020.103188","article-title":"Pseudoprogression versus true progression in glioblastoma patients: a multiapproach literature review: part 1\u2014molecular, morphological and clinical features","volume":"157","author":"Le Fevre","year":"2021","journal-title":"Crit Rev Oncol Hematol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdac137\/45505666\/vdac137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/4\/1\/vdac137\/47936857\/vdac137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/4\/1\/vdac137\/47936857\/vdac137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T23:18:32Z","timestamp":1671146312000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdac137\/6674265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdac137","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"vdac137"}}